The United States of America v. Gilead Sciences, Inc. et al

Track this case

Case overview

Case Number:

1:19-cv-02103

Court:

Delaware

Nature of Suit:

Patent

Judge:

Maryellen Noreika

Firms

Companies

Sectors & Industries:

  1. November 02, 2022

    Gov't Lodges Rival Early Win Bid In Gilead HIV Patent Row

    The U.S. government has urged a Delaware federal judge to award it partial summary judgment in its patent suit against Gilead Sciences Inc. over two brand name HIV treatments that purportedly violate four government-owned patents, arguing there's no question that Gilead's drug Truvada infringes at least one claim in two of the asserted patents.

  2. October 27, 2022

    Gilead Seeks Win In Gov't's 'Unprecedented' HIV Drug IP Suit

    Gilead asked a Delaware federal court to hand it a win Thursday in the government's suit alleging its PrEP HIV drugs infringe the U.S. Department of Health and Human Services' patents, arguing that the lawsuit is "extraordinary and unprecedented" and HHS doesn't have the authority to sue for infringement.

  3. March 24, 2022

    IP Forecast: Fed. Circ. To Mull Arthrex's Latest USPTO Fight

    Arthrex will argue next week that the Federal Circuit must undo the Patent Trial and Appeal Board's invalidation of its suture patent because the patent office’s interim leader lacks the power to review that ruling under a U.S. Supreme Court decision involving the company. Here's a look at where that case stands — plus all the other major intellectual property matters on deck in the coming week.

  4. March 09, 2022

    CDC Told To Keep Story Straight In HIV Patent Fight

    In a ruling unsealed Wednesday, a federal judge told government researchers to provide more consistent testimony regarding how the Centers for Disease Control and Prevention managed intellectual property related to research behind an HIV treatment that both the CDC and Gilead Sciences Inc. later claimed to have invented.

  5. December 16, 2021

    IP Forecast: Feds To Spar With Gilead Over CEO's Testimony

    Gilead Sciences will ask a Delaware federal judge next week to block the federal government from deposing the pharmaceutical company's CEO in a high-profile patent case over allegations Gilead made billions by selling HIV medications using research funded by taxpayers. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.

  6. January 28, 2021

    Feds Can't Dodge Gilead HIV Patent Counterclaims

    A Delaware federal judge Thursday denied the federal government's bid to toss Gilead Sciences' counterclaims in a case accusing the biotech company of infringing four government-owned patents for an HIV treatment.

  7. October 30, 2020

    Feds Pressed On Bid To Nix Gilead HIV Patent Counterclaims

    In a case alleging Gilead infringed four government-owned patents for an HIV treatment, a Delaware federal judge grilled the U.S. Department of Health and Human Services on Friday when the agency argued that it's immune from the drug company's inequitable conduct counterclaims.

  8. July 27, 2020

    Gilead Slams HHS' 'Perverse' Requests In HIV Drug IP Battle

    Gilead has fired back at the U.S. Department of Health and Human Services' requests to wipe out counterclaims against the agency in a patent dispute over an HIV treatment, calling the federal government's claims that it's immune from inequitable conduct defenses "perverse."

  9. May 15, 2020

    HHS Says Gilead Can't Allege Misconduct In HIV Drug IP Suit

    The U.S. Department of Health and Human Services urged a Delaware federal judge Friday to throw out Gilead's counterclaims against the agency in its suit accusing the drugmaker of infringing its patents for an HIV treatment, arguing it can't accuse the government of inequitable conduct in obtaining its own patents.

  10. January 24, 2020

    Gilead Says CDC Broke Promises After Taking Free HIV Drugs

    The Centers for Disease Control and Prevention took free drugs from Gilead to research HIV but then kept the resulting inventions to itself, in violation of several contracts, the drugmaker said after the government accused it of infringement.